Trial Profile
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2020
Price :
$35
*
At a glance
- Drugs Metformin (Primary) ; R-verapamil (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Center Laboratories
- 10 Jul 2020 Primary endpoint (The HbA1c treatment effect among CS02 groups and the Placebo group) has been met.
- 10 Jul 2020 Topline Results published in Center Laboratories Media Release
- 08 Jun 2020 Status changed from recruiting to completed.